Human Genetic Variation Alters Anthrax Toxin Sensitivity
Martchenko, Candille et al., PNAS
Researchers at Stanford University School of Medicine show that genetic variation affecting capillary morphogenesis gene 2, or CMG2, dramatically alters toxin sensitivity in humans. In its analysis, the team reports on "a CMG2 single-nucleotide polymorphism occurring frequently in African and European populations [that they found] independently altered toxin uptake." The group goes on to suggest "testing of genomically characterized human cell populations may offer a broadly useful strategy for elucidating effects of genetic variation on infectious disease susceptibility."
FDA Updates Warfarin Labeling with PGx-Guided Dosing Ranges
February 03, 2010
The FDA updated the labeling for warfarin on Jan. 22 to include PGx-guided dosing ranges. FDA's Lesko explained that the labeling provides dosing ranges in order to give doctors the flexibility to consider their patients clinical factors when determining the appropriate maintenance dose of the anticoagulant.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios
July 13, 2011 / Pharmacogenomics Reporter - FDA Looks into Pradaxa Bleeding Risk; What Does it Mean for PGx-Guided Warfarin Dosing?
December 14, 2011 / Pharmacogenomics Reporter - NIH Launches Large Randomized Trial to Determine Utility of PGx-based Warfarin Dosing
February 18, 2009 / Pharmacogenomics Reporter - When Might Warfarin PGx Be Better Than Pradaxa? Stakeholders Weigh In
October 27, 2010 / Pharmacogenomics Reporter - FDA Official Says Vectibix/Erbitux Relabeling May Guide Sponsors on Agency's Criteria for Accepting Retrospective Data
October 7, 2009 / Pharmacogenomics Reporter